Niro Ramachandran - Nov 19, 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Chief Business Officer
Signature: /s/ Niro Ramachandran, Ph.D., by Brian McKelligon, as Attorney-in-Fact
Stock symbol: AKYA
Transactions as of: Nov 19, 2024
Transactions value $: $0
Form type: 4
Date filed: 11/21/2024, 05:19 PM
Previous filing: Mar 25, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award	$0	+87.5K	+42.08%	$0.00	295K	Nov 19, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest as to 50% on the first anniversary of the first day of the month subsequent to the date of grant (the "First Vesting Date") with the remainder vesting as follows: 25% on the date that is three months following the First Vesting Date; 25% on the date that is six months following the First Vesting Date; 25% on the date that is nine months following the First Vesting Date; and 25% on the date that is twelve months following the First Vesting Date.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.

Content

The restricted stock units shall vest as to 50% on the first anniversary of the first day of the month subsequent to the date of grant (the "First Vesting Date") with the remainder vesting as follows: 25% on the date that is three months following the First Vesting Date; 25% on the date that is six months following the First Vesting Date; 25% on the date that is nine months following the First Vesting Date; and 25% on the date that is twelve months following the First Vesting Date.

Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.